Literature DB >> 35718707

Making a mouse out of a molehill: how precision modeling repurposes drugs for congenital giant nevi.

Katerina Grafanaki1, Glenn Merlino2, Chi-Ping Day3.   

Abstract

Patients with congenital giant nevi (CGN), which can compromise quality of life and progress to melanoma, have limited treatment options. Choi et al. have demonstrated that topical application of a proinflammatory hapten for alopecia treatment [squaric acid dibutylester (SADBE)] caused nevus regression and prevented melanoma in an Nras mouse CGN model. Their results demonstrate the promise of repurposing drugs through precision modeling. Published by Elsevier Inc.

Entities:  

Keywords:  M1 macrophages; Nras; congenital giant nevi (CGN); drug repurposing; genetically engineered mice (GEM); squaric acid dibutylester (SADBE)

Mesh：

Year:  2022        PMID： 35718707      PMCID： PMC9308749          DOI： 10.1016/j.trecan.2022.06.004

Source DB:  PubMed          Journal:  Trends Cancer        ISSN： 2405-8025


  8 in total

1.  Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma.

Authors:  Olga Shakhova; Daniel Zingg; Simon M Schaefer; Lisette Hari; Gianluca Civenni; Jacqueline Blunschi; Stéphanie Claudinot; Michal Okoniewski; Friedrich Beermann; Daniela Mihic-Probst; Holger Moch; Michael Wegner; Reinhard Dummer; Yann Barrandon; Paolo Cinelli; Lukas Sommer
Journal:  Nat Cell Biol       Date:  2012-07-08       Impact factor: 28.824

2.  Giant Congenital Melanocytic Nevus Treated With Trametinib.

Authors:  Adnan Mir; Nnenna G Agim; Alex A Kane; Shellie C Josephs; Jason Y Park; Kathleen Ludwig
Journal:  Pediatrics       Date:  2019-03       Impact factor: 7.124

Review 3.  The role of macrophages in skin homeostasis.

Authors:  Diana A Yanez; Richard K Lacher; Aurobind Vidyarthi; Oscar R Colegio
Journal:  Pflugers Arch       Date:  2017-02-23       Impact factor: 3.657

4.  Topical therapy for regression and melanoma prevention of congenital giant nevi.

Authors:  Yeon Sook Choi; Tal H Erlich; Max von Franque; Inbal Rachmin; Jessica L Flesher; Erik B Schiferle; Yi Zhang; Marcello Pereira da Silva; Alva Jiang; Allison S Dobry; Mack Su; Sharon Germana; Sebastian Lacher; Orly Freund; Ezra Feder; Jose L Cortez; Suyeon Ryu; Tamar Babila Propp; Yedidyah Leo Samuels; Labib R Zakka; Marjan Azin; Christin E Burd; Norman E Sharpless; X Shirley Liu; Clifford Meyer; William Gerald Austen; Branko Bojovic; Curtis L Cetrulo; Martin C Mihm; Dave S Hoon; Shadmehr Demehri; Elena B Hawryluk; David E Fisher
Journal:  Cell       Date:  2022-05-12       Impact factor: 66.850

5.  Local Inhibition of MEK/Akt Prevents Cellular Growth in Human Congenital Melanocytic Nevi.

Authors:  Thomas Rouillé; Selim Aractingi; Natacha Kadlub; Sylvie Fraitag; Alexandre How-Kit; Antoine Daunay; Mikael Hivelin; Philippe Moguelet; Arnaud Picard; Romain H Fontaine; Sarah Guégan
Journal:  J Invest Dermatol       Date:  2019-05-03       Impact factor: 8.551

Review 6.  Genetics of melanocytic nevi.

Authors:  Mi Ryung Roh; Philip Eliades; Sameer Gupta; Hensin Tsao
Journal:  Pigment Cell Melanoma Res       Date:  2015-11       Impact factor: 4.693

7.  Interferon-γ links ultraviolet radiation to melanomagenesis in mice.

Authors:  M Raza Zaidi; Sean Davis; Frances P Noonan; Cari Graff-Cherry; Teresa S Hawley; Robert L Walker; Lionel Feigenbaum; Elaine Fuchs; Lyudmila Lyakh; Howard A Young; Thomas J Hornyak; Heinz Arnheiter; Giorgio Trinchieri; Paul S Meltzer; Edward C De Fabo; Glenn Merlino
Journal:  Nature       Date:  2011-01-19       Impact factor: 49.962

Review 8.  Melanoma in congenital melanocytic naevi.

Authors:  V A Kinsler; P O'Hare; N Bulstrode; J E Calonje; W K Chong; D Hargrave; T Jacques; D Lomas; N J Sebire; O Slater
Journal:  Br J Dermatol       Date:  2017-04-04       Impact factor: 9.302
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.